HACKENSACK, N.J.,
Sept. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc.
(NASDAQ: CSBR), a company engaged in the development and sale of
advanced technology solutions and products to personalize the
development and use of oncology drugs, today announced the
publication entitled "Patient-derived xenografts (PDX) effectively
capture responses to oncology therapy in a heterogeneous cohort of
patients with solid tumors" in the journal Annals of
Oncology. Annals of Oncology is published by
the European Society for Medical oncology (ESMO), the leading
European professional organization for medical oncology in
Europe. Building on earlier
clinical correlation data, this study further demonstrates that PDX
models accurately predict patient response to oncology drugs with
remarkable 85% positive predictive value.
In the published study, tumors obtained from surgical or biopsy
procedures from 237 cancer patients with a variety of solid tumors
(including breast, colorectal, ovarian, lung, gastroesophageal,
pancreatic cancer and sarcoma) were implanted into immunodeficient
mice to establish individual PDX models. Treatment
responses in the corresponding PDX models were compared with 129
treatments that were administered to the same patients clinically.
In addition, consistent with the existing literature, PDX
models faithfully preserved the genetic landscape of the original
parental tumor.
"Patient responses correlated well with matching PDXs in a
large, heterogeneous population thus demonstrating the utility of
this platform for preclinical drug-testing and personalized cancer
treatment. Our experience shows us that these models are an
accurate tool that can be used in planning clinical trials,
identifying patient populations most likely to benefit from
oncology therapeutics, and biomarker development," said
Angela Davies, M.D., Chief Medical
Officer at Champions Oncology. "We would like to thank our
collaborators and patients that contributed to this dataset,
creating a valuable PDX resource for the oncology community."
Manuel Hidalgo, M.D., Ph.D.,
Professor of Medicine at Harvard Medical
School, noted that, "Pharma should be adopting greater use
of larger PDX cohorts to 'simulate' clinical trials early in drug
development. As demonstrated in this study, the molecular
correlation of these models with the primary tumor is extremely
high allowing us to identify key markers for trial success and
personalized treatments."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's
TumorGraft technology platform is a novel approach to personalizing
cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please visit
www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-announces-publication-highlighting-clinical-correlation-between-patient-derived-xenograft-pdx-model-responses-and-patient-responses-to-oncology-therapies-300521091.html
SOURCE Champions Oncology, Inc.